Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease

Current Oncology

View Publication Info
 
 
Field Value
 
Title Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease
 
Creator Perera, S.
Kelly, D.
O'Kane, G. M.
 
Subject Hepatocellular carcinoma
immunotherapy
checkpoint inhibitors
nivolumab
pembrolizumab
atezolizumab
lenvatinib
sorafenib
systemic therapy
tyrosine kinase inhibitors
 
Description  The results of the sharp trial established sorafenib, a tyrosine kinase inhibitor (TKI), as the sole first-line treatment option in advanced hepatocellular carcinoma (HCC) for more than a decade. In 2020, there has been a surge in new therapies for hcc, including immunotherapeutic strategies and the approval of a number of novel tkis. In addition to sorafenib, lenvatinib and combination atezolizumab–bevacizumab now represent standard first-line treatment options. As those systemic options begin to be better utilized, assurance of adequate liver function and optimal timing are required to improve patient outcomes. Furthermore, sequencing of the agents will have to be carefully tailored, given the increasing armamentarium of choices. Here, we discuss the role of lenvatinib and sorafenib in the first-line management of HCC.
 
 
Publisher Multimed Inc.
 
Date 2020-08-16
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
text/html
 
Identifier http://www.current-oncology.com/index.php/oncology/article/view/7159
10.3747/co.27.7159
 
Source Current Oncology; Vol. 27 No. S3 (2020): Evolving Treatment Landscape of Hepatocellular Carcinoma: more choices, more responsibility
1718-7729
1198-0052
 
Language eng
 
Relation http://www.current-oncology.com/index.php/oncology/article/view/7159/9549
http://www.current-oncology.com/index.php/oncology/article/view/7159/9585
 
Rights Copyright (c) 2020 Multimed Inc.
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library